Cell Reports Medicine (Oct 2021)
Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge model
- Ami Patel,
- Jewell N. Walters,
- Emma L. Reuschel,
- Katherine Schultheis,
- Elizabeth Parzych,
- Ebony N. Gary,
- Igor Maricic,
- Mansi Purwar,
- Zeena Eblimit,
- Susanne N. Walker,
- Diana Guimet,
- Pratik Bhojnagarwala,
- Opeyemi S. Adeniji,
- Arthur Doan,
- Ziyang Xu,
- Dustin Elwood,
- Sophia M. Reeder,
- Laurent Pessaint,
- Kevin Y. Kim,
- Anthony Cook,
- Neethu Chokkalingam,
- Brad Finneyfrock,
- Edgar Tello-Ruiz,
- Alan Dodson,
- Jihae Choi,
- Alison Generotti,
- John Harrison,
- Nicholas J. Tursi,
- Viviane M. Andrade,
- Yaya Dia,
- Faraz I. Zaidi,
- Hanne Andersen,
- Mohamed Abdel-Mohsen,
- Mark G. Lewis,
- Kar Muthumani,
- J. Joseph Kim,
- Daniel W. Kulp,
- Laurent M. Humeau,
- Stephanie J. Ramos,
- Trevor R.F. Smith,
- David B. Weiner,
- Kate E. Broderick
Affiliations
- Ami Patel
- Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
- Jewell N. Walters
- Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA
- Emma L. Reuschel
- Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
- Katherine Schultheis
- Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA
- Elizabeth Parzych
- Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
- Ebony N. Gary
- Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
- Igor Maricic
- Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA
- Mansi Purwar
- Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
- Zeena Eblimit
- Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA
- Susanne N. Walker
- Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
- Diana Guimet
- Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA
- Pratik Bhojnagarwala
- Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
- Opeyemi S. Adeniji
- Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
- Arthur Doan
- Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA
- Ziyang Xu
- Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
- Dustin Elwood
- Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA
- Sophia M. Reeder
- Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
- Laurent Pessaint
- Bioqual, Rockville, MD 20852, USA
- Kevin Y. Kim
- Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
- Anthony Cook
- Bioqual, Rockville, MD 20852, USA
- Neethu Chokkalingam
- Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
- Brad Finneyfrock
- Bioqual, Rockville, MD 20852, USA
- Edgar Tello-Ruiz
- Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
- Alan Dodson
- Bioqual, Rockville, MD 20852, USA
- Jihae Choi
- Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
- Alison Generotti
- Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA
- John Harrison
- Bioqual, Rockville, MD 20852, USA
- Nicholas J. Tursi
- Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
- Viviane M. Andrade
- Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA
- Yaya Dia
- Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
- Faraz I. Zaidi
- Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
- Hanne Andersen
- Bioqual, Rockville, MD 20852, USA
- Mohamed Abdel-Mohsen
- Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
- Mark G. Lewis
- Bioqual, Rockville, MD 20852, USA
- Kar Muthumani
- Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
- J. Joseph Kim
- Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA
- Daniel W. Kulp
- Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
- Laurent M. Humeau
- Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA
- Stephanie J. Ramos
- Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA
- Trevor R.F. Smith
- Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA
- David B. Weiner
- Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA; Corresponding author
- Kate E. Broderick
- Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA; Corresponding author
- Journal volume & issue
-
Vol. 2,
no. 10
p. 100420
Abstract
Summary: Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, has had a dramatic global impact on public health and social and economic infrastructures. Here, we assess the immunogenicity and anamnestic protective efficacy in rhesus macaques of an intradermal (i.d.)-delivered SARS-CoV-2 spike DNA vaccine, INO-4800, currently being evaluated in clinical trials. Vaccination with INO-4800 induced T cell responses and induced spike antigen and RBD binding antibodies with ADCP and ADCD activity. Sera from the animals neutralized both the D614 and G614 SARS-CoV-2 pseudotype viruses. Several months after vaccination, animals were challenged with SARS-CoV-2 resulting in rapid recall of anti-SARS-CoV-2 spike protein T cell and neutralizing antibody responses. These responses were associated with lower viral loads in the lung. These studies support the immune impact of INO-4800 for inducing both humoral and cellular arms of the adaptive immune system, which are likely important for providing durable protection against COVID-19 disease.
